SEC Filing Summary: Cerulean Pharma Inc. (Form 8-K)
Business Context and Reporting Period
Cerulean Pharma Inc. filed this Current Report on Form 8-K on November 13, 2014. The filing references operational highlights for the quarter ended September 30, 2014, and anticipated clinical milestones for the remainder of 2014 and 2015. Note: The input metadata lists "Dare Bioscience, Inc.", but the filing text explicitly identifies the registrant as "Cerulean Pharma Inc."
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is not included in the provided text.
Material Changes
The filing announces the issuance of a press release regarding operational highlights and clinical milestones. No specific quantitative material changes versus prior periods are detailed in the text of the 8-K itself.
Guidance, Outlook, and Risks
Management provided anticipated clinical milestones for the remainder of 2014 and 2015 in the referenced press release. The filing explicitly states that the information under Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section nor incorporated by reference unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name (Cerulean Pharma Inc. vs. Dare Bioscience, Inc.) in the context of your investment records.
- Review Exhibit 99.1 (Press Release dated November 13, 2014) for specific financial figures and operational data not present in the 8-K text.
- Confirm the specific clinical milestones anticipated for late 2014 and 2015 as outlined in the press release.
- Note that the operational data is furnished, not filed, and may not be incorporated by reference in other filings.